FibroBiologics has filed a U.S. patent for a novel cell-based technology that engineers living cells to continuously produce therapeutic peptides like GLP-1 inside the body. This approach aims to replace frequent injections or pills for conditions such as diabetes and weight loss by administering engineered cells once, which then act as peptide factories. The technology also has potential applications in gastrointestinal, autoimmune, inflammatory diseases, and more. It includes safety features and tunable peptide production, offering a promising alternative to current peptide therapies.
FibroBiologics' new patent application for in-body peptide production technology is the subject, with Pluang market data providing context. As of Oct 07, 2026 19:12 WIB, 44 of 100 priced Health-sector US stocks rose while 50 fell. Notable movers include Danaher Corporation at USD 220.38 with a +2.24% change and Abeona Therapeutics Inc at USD 5.11 with a +2.00% change.
Ripple's payment system now includes a recovery process for cross-border transfers that fail after XRP withdrawal but before deposit confirmation. This process allows the system to retry payments multiple times over several hours and can convert XRP ...
Commvault has named Matthew Stauble as its new Chief Customer Officer to lead its global customer engineering teams, including sales engineering, customer success, and support. Stauble brings extensive experience from Alteryx and Palo Alto Networks, ...
Cincinnati Financial Corporation will release its third-quarter 2026 earnings after market close on October 26, 2026. The company will hold a conference call to discuss the results on October 27 at 11 a.m. ET, accessible via their investor website. T...
TE Connectivity plc will announce its financial results for the fourth quarter and full fiscal year 2026 on October 28, 2026, before the market opens. The company will host a conference call for investors at 8:30 a.m. ET on the same day, providing de...
Leifras, a leading Japanese youth sports company, has launched a new corporate communications platform called "Story of LEIFRAS" in its 25th anniversary year. The platform aims to share deeper stories behind the company's business, philosophy, people...
